Alebund
Shanghai, CN · 12 known investors
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease. The company operates manufacturing facilities in China and has established commercial networks across major Chinese cities and hospitals.
Investors · 12
Also in the syndicate · 5
Funding
SEC filings, press & company announcements- Undisclosed amountSeries B+Sep 2021
3H Health Investment (lead), Loyal Valley Capital (lead), Morningside Ventures (lead), 3E Bioventures Capital, HT Capital, Lilly Asia Ventures, Octagon Capital, Quan Capital, Sherpa Healthcare Partners, Verition Fund Management, YuanBio Venture Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026Frequently asked questions
- What does Alebund do?
- An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease. The company operates manufacturing facilities in China and has established commercial networks across major Chinese cities and hospitals.
- Who are Alebund's investors?
- Alebund's investors include LAV, Lilly Asia Ventures, Quan Capital, 3E Bioventures Capital, 3H Health Investment, Sherpa Healthcare Partners, YuanBio Venture Capital.
- Where is Alebund headquartered?
- Alebund is headquartered in Shanghai, CN.